Navigation Links
FDA Accepts Ranexa(R) sNDA and NDA for Filing
Date:11/19/2007

PALO ALTO, Calif., Nov 19 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that its supplemental new drug application (sNDA) and new drug application (NDA) for Ranexa(R) (ranolazine extended- release tablets) have both been accepted for filing. The Prescription Drug User Fee Act (PDUFA) action date for both applications is July 27, 2008.

The sNDA seeks an expansion to the approved product labeling for Ranexa(R) (ranolazine extended-release tablets) to include a first line angina indication and a significant reduction in cautionary language. The sNDA is being reviewed by the FDA Division of Cardiovascular Renal Products.

After receiving this sNDA submission from CV Therapeutics, the FDA initiated, and has now accepted for filing, a separate NDA on behalf of the Company to provide a clinical review of a potential labeling change to add reduction of hemoglobin A1c (HbA1c) in coronary artery disease patients with diabetes. This NDA is being reviewed by the FDA Division of Metabolism and Endocrinology Products.

"With the Ranexa sNDA and NDA now accepted for filing, the NDA under review for regadenoson and our marketing authorization application for ranolazine under review in Europe, we are very excited to have several major applications in process and are looking forward to multiple potential approvals in 2008," said Louis G. Lange, CV Therapeutics chairman and chief executive officer.

In accordance with a special protocol assessment agreement between the FDA and CV Therapeutics, the Company believes that data from the MERLIN TIMI-36 study could support expansion of the existing Ranexa indication
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
2. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
3. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
4. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
5. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
6. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
7. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
8. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
9. 3 strikes, youre out? Refiling of Amendment to Change Constitution to Criminalize Stem Cell Cures Shows Trouble with Anti-Cures Cause
10. Prana Announces Filing of Annual Report
11. AMDL Announces Filing of Extension on Third Quarter 2007 Form 10-QSB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... METTLER TOLEDO’s newly improved XS balance line includes ... well as a dual range microbalance . As ... weighing pan delivers results up to twice as fast, ... design details mean users no longer need to suffer ... in front of the balance. Barbara Bienlein, medical specialist ...
(Date:10/1/2014)... Mass. , Oct. 1, 2014  Pressure BioSciences, ... leader in the development and sale of high pressure-based ... today announced it has been invited to present at ... Warsaw , Poland.  The Conference will ... 2, 2014.  Mr. Richard T. Schumacher , President ...
(Date:10/1/2014)... , Oct. 1, 2014  Spherix Incorporated (Nasdaq: ... fostering and monetization of intellectual property, announced today ... VTech and Uniden in the U.S. District Court ... has been rescheduled for November 10, ... 2, 2014.  The Court Order setting the Markman ...
(Date:10/1/2014)... CA (PRWEB) October 01, 2014 As the ... leaves no room for doubt that this century would mark ... in the field of medicine science. The fact that the ... is not unknown to the scientific community. Almost half of ... and therefore can be prevented with medical care and intervention. ...
Breaking Biology Technology:METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 2METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 2Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 4Markman Hearing Date for VTech and Uniden Litigation Now Set for November 10, 2014 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 3
... announces the introduction of web-based Spanish-language ... La., June 9 Lee Pryor, Portico,s CEO,commented, ... Spanish will,enable small and mid-size companies worldwide to ... transmitidos por la sangre, the Spanish,version of one ...
... Practices ... Costs, SAN FRANCISCO and BRUSSELS, June 7 ... Epidemiology and Prevention warned,today that recent research demonstrates ... are closely related, and that both disorders,have significant ...
... transition from imitator to innovator in health-related products, according to ... facing that country,s health biotech industry. , In ... Global Health (MRC), says South America,s largest and most populous ... a major global player. It is held back, however, ...
Cached Biology Technology:LMXonline Offers Spanish-Language Safety and Health Training Library 2IDF Urges Healthcare Providers to Address the Relationship Between Type 2 Diabetes and Sleep Apnea 2IDF Urges Healthcare Providers to Address the Relationship Between Type 2 Diabetes and Sleep Apnea 3IDF Urges Healthcare Providers to Address the Relationship Between Type 2 Diabetes and Sleep Apnea 4Brazil's biotech firms: From imitators to innovators in health-related products 2Brazil's biotech firms: From imitators to innovators in health-related products 3Brazil's biotech firms: From imitators to innovators in health-related products 4Brazil's biotech firms: From imitators to innovators in health-related products 5Brazil's biotech firms: From imitators to innovators in health-related products 6
(Date:9/30/2014)... report that a new class of chemical compounds ... They have also pinpointed the relevant target enzyme, ... , Researchers led by LMU,s Professor Angelika ... Universitt Mnchen have identified a class of chemicals ... fight against malignant tumors. The compound is itself ...
(Date:9/30/2014)... This news release is available in German . ... differ in their behavioural response to risky situations such ... Institute for Ornithology now found in a long-term study ... correlates with both metabolic rate and ambient temperature. High ... risk-taking behaviour, as in these scenarios birds were more ...
(Date:9/30/2014)... Ill. (September 30, 2014) People who suffer from ... do to control their asthma besides properly taking medications ... new article in the Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), asthma sufferers ... their lifestyle. The woman described in the Annals article ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... the back of a leaf and the tip is different from ... Arabidopsis plant superficially appears to be bilaterally symmetrical, or the ... fool you; there is an underlying asymmetry between the left and ... to discover it. The story begins with the mechanism by which ...
... an enzyme that is involved in a modification pathway ... no similarity to other known proteins, it may be ... Studies on a number of pathogenic bacteria ... an enzyme called elongation factor P (EF-P) is chemically ...
... multidisciplinary team of researchers at MIT and in Spain ... electronic behavior of noncrystalline materials, which may eventually play ... organic LED lights and printable, flexible electronic circuits. ... not previously been applied in physics or chemistry. Even ...
Cached Biology News:Is your leaf left-handed? 2Is your leaf left-handed? 3New technique allows simulation of noncrystalline materials 2New technique allows simulation of noncrystalline materials 3
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Rac1/2/3 (L129) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
In plasmid or lambda vector. Please inquire for more details!...
ANTI-RAT ADHESION MARKERS, CDs, CYTOKINES, ETC Rat ICAM PE - Mouse IgG1...
Biology Products: